Pharmaceutical

Auburn University opened the $16.6 million Pharmaceutical Research Building in June of 2017 in Auburn, Ala. Providing laboratories and offices for the Harrison School of Pharmacy, the 37,000-sf facility features collaborative open research spaces that are shared by multiple faculty members. A vivarium is located on the first floor of the building, and the second floor houses the Specialized Pharmaceutical and Experimental Center for Translational Research and Analysis (SPECTRA). The duration of construction was 16 months. 

Bayer HealthCare opened a $100 million pharmaceutical testing laboratory in July of 2017 in Berkeley, Calif. Featuring a sophisticated HVAC system with robust filtration controls, the three-story facility will support research, development, and quality control operations for the production of Bayer’s hemophilia A treatments. LEED Gold sustainable design certification will be sought for the project.

Eli Lilly completed a $90 million expansion of its San Diego biotechnology center in June of 2017. The 180,000-sf facility features the Life Science studio, a technology-rich laboratory suite supporting advanced drug discovery and development. Promoting global collaboration and innovation in the design, synthesis, and screening of molecules, the center will accommodate research in immunology, diabetes, oncology, and neurodegeneration. 

Pfizer broke ground in June of 2017 on a $200 million research and development facility in Chesterfield, Mo. Housing the BioTherapeutics Pharmaceutical Sciences group, the 295,000-sf project will enable the advancement of Pfizer’s biologics, vaccines, and gene therapy portfolio. Designed by Forum and EwingCole, the facility will feature flexible laboratories, open offices, and collaboration spaces with advanced conferencing technologies.

Jinyu Bio-technology will break ground in July of 2017 on a vaccine research facility in the Kansas State University Office Park. Supporting the development of new animal health products, the project will include a 2,400-sf lab, three offices, and 800 sf of cleanroom space. Completion is expected in 2018. The siting of the lab near the National Bio and Agro-Defense Facility, currently under construction, will support research and development synergies with government, academic, and industry partners. Jinyu Bio-technology is based in Hohhot, China.

Merck and Stelis Biopharma opened a joint bioprocess scale-up lab in May of 2017 in Bengaluru, India. Located in the Jigani industrial park, the facility will provide end-to-end solutions from process development to scale-up manufacturing for pre-clinical, clinical, and commercial supply of biological APIs (active pharmaceutical ingredients). A cGMP manufacturing plant featuring Merck's portfolio of Mobius® bioprocessing equipment is also under construction at the site. 

Cody Laboratories began construction in April of 2017 on a $50 million pharmaceutical production plant in Cody, Wyo. Sited on 21 acres, the 43,000-sf facility will manufacture prescription drugs. Completion is expected in late 2018.

The New York Stem Cell Foundation (NYCSF) opened its 40,000-sf Research Institute in Manhattan in April of 2017. Designed by Ennead Architects, the project accommodates NYCSF’s headquarters and includes a lecture hall, conference rooms, collaboration areas, and flexible laboratories.

AmerisourceBergen Specialty Group is creating a $113 million pharmaceutical campus in Carrollton, Texas. Designed by Gensler, the 300,000-sf build-to-suit facility will be leased by AmerisourceBergen for 12.5 years and will ultimately accommodate up to 2,000 employees. Occupancy is expected in 2019. AmerisourceBergen is a pharmaceutical sourcing and distribution company based in Valley Forge, Pa. 

Veterinary pharmaceutical firm HIPRA is planning to begin construction in mid-2017 on its North American headquarters in Mantua Township, N.J. Located on 25 acres in the South Jersey Technology Park at Rowan University, the 375,000-sf facility will house research and development labs for the creation of animal health vaccines. The $100 million project will be developed in several phases and will include manufacturing, distribution, and warehouse space. HIPRA is based in Girona, Spain. 

Samsung Biologics is constructing a 1.3 million-sf pharmaceutical production facility in the Songo International Business District in Incheon, South Korea. Accommodating twelve 15-liter bioreactors, the five-story facility will be the world’s largest biologics manufacturing plant when it opens in 2018. Ground was broken on the project in November of 2015.

Canadian pharmaceutical company Apotex began construction in spring of 2017 on a $184 million research and advanced manufacturing center in Miramar, Fla. The facility will house the firm’s U.S. headquarters as well as accommodating R&D, production, and packaging operations. Completion is expected in early 2019.

The Research Institute of Molecular Pathology opened its new facility in the Vienna Biocenter in March of 2017. Designed by ATP Architects and Engineers, the highly flexible building will accommodate 200 investigators engaged in biomedical research and development. Founded in 1985, the Research Institute of Molecular Pathology is funded by research grants and the sponsorship of founding company Boehringer Ingelheim, who invested $57 million in the project. The duration of construction was two and a half years.

Adaptimmune opened its new headquarters in the Philadelphia Navy Yard in March of 2017 in Philadelphia. The 47,400-sf project will include an advanced cGMP manufacturing facility to support the development and commercialization of novel engineered immunotherapies for cancer. The facility was designed by DIGSAU and is expected to attain LEED Gold in the Core & Shell rating system. CBRE’s Life Science Advisory and Project Management Group assisted Adaptimmune during the construction phase of the project.

Just Biotherapeutics is integrating PODs® made by G-CON Manufacturing into the construction of its biologics manufacturing building in China. Located in the Hangzhou Economic & Technology Development Area (HEDA), the cGMP plant will utilize the prefabricated cleanroom units to create a highly flexible and efficient facility. Completion is expected by early 2018.